Aura Biosciences (NASDAQ:AURA – Get Free Report) is expected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.3681) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, analysts expect Aura Biosciences to post ($1.61) EPS for the current fiscal year and ($1.39) EPS for the next fiscal year.
Aura Biosciences Stock Performance
AURA stock traded up $0.06 during trading on Wednesday, hitting $6.29. 75,709 shares of the company traded hands, compared to its average volume of 562,300. Aura Biosciences has a 1 year low of $4.73 and a 1 year high of $9.53. The company has a 50-day moving average of $6.61 and a 200-day moving average of $6.70. The firm has a market capitalization of $652.85 million, a PE ratio of -3.60 and a beta of 0.41.
Analyst Upgrades and Downgrades
AURA has been the subject of several analyst reports. HC Wainwright dropped their price target on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, October 12th. Finally, Wall Street Zen lowered shares of Aura Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $17.50.
View Our Latest Stock Analysis on AURA
About Aura Biosciences
Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.
Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.
See Also
- Five stocks we like better than Aura Biosciences
- Advanced Micro Devices’ Q3 Results Answer a Big Question, But Another Remains
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
